| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - There is limited data regarding the use of activated recombinant factor VII (rFVIIa) in anticoagulated patients requiring reversal. Aims: To identify and describe characteristics of subjects who received rFVIIa as part of emergency treatment aimed at improving hemostasis. Settings and Design: Data was obtained from an international peer-reviewed registry haemostasis.com. This registry contains data reported by physicians, who had elected to use rFVIIa to control bleeding in an emergency clinical situation. The contributors' approval for inclusion in the study was obtained and they were requested to validate and update information. Materials and Methods: Database review of cases receiving rFVIIa to manage bleeding coherent with the use of anticoagulant therapy. Statistical Analysis: The Wilcoxon signed rank test was used to compare requirements for blood products and crystalloids/colloids during the 24h preceding and following rFVIIa administration, as well as changes in the levels of clotting fac
- There is limited data regarding the use of activated recombinant factor VII (rFVIIa) in anticoagulated patients requiring reversal. Aims: To identify and describe characteristics of subjects who received rFVIIa as part of emergency treatment aimed at improving hemostasis. Settings and Design: Data was obtained from an international peer-reviewed registry haemostasis.com. This registry contains data reported by physicians, who had elected to use rFVIIa to control bleeding in an emergency clinical situation. The contributors' approval for inclusion in the study was obtained and they were requested to validate and update information. Materials and Methods: Database review of cases receiving rFVIIa to manage bleeding coherent with the use of anticoagulant therapy. Statistical Analysis: The Wilcoxon signed rank test was used to compare requirements for blood products and crystalloids/colloids during the 24h preceding and following rFVIIa administration, as well as changes in the levels of clotting fac (en)
- Existují pouze omezená data o použití aktivovaného rekombinantního faktoru VII (rFVIIa) u pacientů na antikoagulační terapii, u nichž je potřebný zvrat této antikoagulace. Cílem práce bylo identifikovat pacienty, kterým byl podán rFVIIa jako součást emergentní léčby ke zlepšení hemostázy. Data byla získána z mezinárodního kontrolovaného registru haemostasis.com. (registr obsahuje data hlášená lékaři, kteří se rozhodli použít rFVIIa ke stavění krvácení v emergentní klinické situaci). Bylo nalezeno 19 pacientů, kterým byl podán rFVIIa (medián dávky: 87.35 microg/kg; rozpětí: 20.0-106.0 microg/kg), u všech těchto pacientů selhala tradiční antidota a krevní produkty. Po podání se krvácení zastavilo u 10, podstatně snížilo u 5 a zpomalilo u zbývajících 3 pacientů. Požadavky na krevní produkty a krystaloidy/koloidy se po podání rFVIIa snížily ( P < 0.05) (cs)
|
| Title
| - Use of recombinant factor VIIa for emergency reversal of anticoagulation
- Use of recombinant factor VIIa for emergency reversal of anticoagulation (en)
- Použítí rekombinantních faktorů VIIa v pohotovostním obratu antikoagulace (cs)
|
| skos:prefLabel
| - Use of recombinant factor VIIa for emergency reversal of anticoagulation
- Use of recombinant factor VIIa for emergency reversal of anticoagulation (en)
- Použítí rekombinantních faktorů VIIa v pohotovostním obratu antikoagulace (cs)
|
| skos:notation
| - RIV/00216208:11120/07:00000882!RIV09-MSM-11120___
|
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| |
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/00216208:11120/07:00000882
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - anticoagulation therapy; bleeding; recombinant activated factor VII; rFVIIa (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| |
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| - Journal of Postgraduate Medicine
|
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Vaněk, Tomáš
- Ingerslev, J.
- Culic, S.
|
| http://linked.open...ain/vavai/riv/wos
| |
| issn
| |
| number of pages
| |
| http://localhost/t...ganizacniJednotka
| |
| is http://linked.open...avai/riv/vysledek
of | |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)